QuidelOrtho and BÜHLMANN Collaborate on Gastrointestinal Biomarker Tests

QuidelOrtho Corporation (San Diego, CA, USA) and BÜHLMANN Laboratories AG (Schönenbuch, Switzerland) have announced the availability of the BÜHLMANN fCAL turbo and fPELA turbo assays on QuidelOrtho's VITROS Systems as an MPA. Both particle-enhanced turbidimetric immunoassays, the fCAL turbo assay for fecal calprotectin measurement aids in the diagnosis of inflammatory bowel disease (IBD) and its differentiation from irritable bowel syndrome, and the fPELA turbo assay for fecal pancreatic elastase aids in the determination of pancreatic insufficiency.

This collaboration addresses key healthcare trends, including the rise of non-invasive diagnostic tools, the demand for cost-effective healthcare solutions, and the growing focus on gastrointestinal and pancreatic health and its systemic impact. The fCAL and fPELA turbo assays exemplify innovation in diagnostics technology, supporting the shift toward tailored medicine and preventive healthcare. The fCAL and fPELA turbo assays are both now available for use on QuidelOrtho's VITROS Systems: VITROS XT 7600 and 5600 Integrated System, as well as VITROS 4600 Chemistry Systems.

These assays contribute to better management of gastrointestinal health, reducing the need for invasive procedures and lowering long-term healthcare costs. Both assays utilize BÜHLMANN's innovative CALEX Cap technology, which simplifies sample extraction and preparation while facilitating safe handling – all seamlessly integrated onto a single VITROS System. The fCAL and fPELA turbo assays' integration with VITROS Systems offers laboratories an efficient workflow for a wide variety of sample collection methods, enhancing flexibility in sample handling and processing.

"The integration of BÜHLMANN's fCAL and fPELA turbo assays with our VITROS Systems represents a significant advancement in IBD and pancreatic insufficiency diagnoses," said Jonathan Siegrist, PhD, Executive Vice President of Research & Development & Chief Technology Officer at QuidelOrtho. "This collaboration allows laboratories to provide fast results to aid in the diagnosis and management of IBD and pancreatic issues, ultimately improving patient care."

"We are thrilled to collaborate with QuidelOrtho to expand the delivery of an efficient, automated solution for fecal biomarker testing," added Christian Eberle, Chief Executive Officer at BÜHLMANN Laboratories AG. "Our assays, combined with the CALEX Cap stool preparation device, optimize stool extraction efficiency to help maximize stability and yield, resulting in robust fecal calprotectin and pancreatic elastase test results. This collaboration between QuidelOrtho and BÜHLMANN Laboratories AG meets evolving patient and provider needs in the era of personalized medicine and preventive healthcare, offering innovative solutions that align with the industry's focus on non-invasive, cost-effective, and patient-centric diagnostic tools."

Related Links:
QuidelOrtho
BÜHLMANN Laboratories